AstraZeneca gets regulatory approvals for two cancer drugs in Japan

AstraZeneca, along with its biologics research and development arm MedImmune, has secured approval from the Japanese ministry of health, labour and welfare for Imfinzi (durvalumab) as maintenance therapy